<!DOCTYPE html><html lang="en"> <head><meta charset="UTF-8"><meta name="description" content="Wesbsite of Dr. Debasis Maity, Urosurgeon in Kolkata"><meta name="viewport" content="width=device-width"><link rel="icon" href="/favicon.ico"><meta name="generator" content="Astro v4.16.13"><title>Discussion</title><link rel="stylesheet" href="/_astro/_topic_.n0qjGj_0.css">
<style>h1[data-astro-cid-nlow4r3u],h2[data-astro-cid-nlow4r3u],h3[data-astro-cid-nlow4r3u],h4[data-astro-cid-nlow4r3u],h5[data-astro-cid-nlow4r3u],h6[data-astro-cid-nlow4r3u]{text-align:center}
</style><script type="module">document.addEventListener("DOMContentLoaded",()=>{document.querySelectorAll("table").forEach(e=>{e.classList.add("table")})});
</script></head> <body> <div class="container">  <section class="hero" data-astro-cid-nlow4r3u> <a href="/" data-astro-cid-nlow4r3u> <div class="hero-content" data-astro-cid-nlow4r3u> <div class="jumbotron" data-astro-cid-nlow4r3u> <h1 class="display-4 text-primary" data-astro-cid-nlow4r3u>Dr. Debasis Maity</h1> <p class="lead text-center text-primary" data-astro-cid-nlow4r3u>Consultant Uro-Surgeon</p> </div> </div> </a> </section>  <div class="card"> <div class="card-header bg-success text-light"> <h2 class="card-title">CA Prostate</h2> </div> <div class="card-body"> <h4 id="d-1-persistently-raised-psa-and-single-negative-prostate-biopsy"><code>D-1) Persistently raised PSA and single negative prostate biopsy:</code></h4>
<p><strong>what next?</strong></p>
<ul>
<li>
<p>The <em>first step is to assess adequacy</em> of initial biopsy –</p>
<p>which depends on:</p>
<ol>
<li>No and location of biopsy cores taken, length of each core,quality of tissue sampled.</li>
<li>Size of prostate (chance of finding any cancer is inversely related to prosate size).</li>
</ol>
</li>
<li>
<p>what next = <strong>repeat biopsy</strong>.</p>
<p><strong>but why?</strong></p>
<ul>
<li>Detection rate on repeat biopsy will be <strong>2 fold higher</strong> in an12 core extended biopsy scheme- (AUA 2012).</li>
<li>Upto <strong>30%</strong> improved detection rate on RPB (EAU-2013).</li>
</ul>
</li>
</ul>
<h4 id="d-2-role-of-new-biochemical-marker"><code>D-2) Role of new biochemical marker:</code></h4>
<p>Aim is to reduce unnecessary Repeat biopsy.</p>
<ul>
<li>
<p><strong>NCCN guideline</strong> (EAU 2013)</p>





















<table><thead><tr><th>%fPSA ( in pt with total PSA 4-10 ng/ml)</th><th>Prostate Biopsy (PB)</th></tr></thead><tbody><tr><td>≤10%</td><td>Do PB</td></tr><tr><td>.>10 - ≤25%</td><td>Intermediate</td></tr><tr><td>≥25%</td><td>No PB</td></tr></tbody></table>
</li>
<li>
<p><strong>FDA approval</strong></p>
<p><strong>Progensa PCA3 assay</strong></p>
<ul>
<li><em>what is this ?</em>
<ul>
<li>This is <span class="text-danger">PCA3 score</span> = ( PCA3 RNA/PSA RNA)</li>
</ul>
</li>
<li>Cut off value=25, in post DRE 1st catch urine. (some used-cut off=35)</li>
<li><em>For whom?</em>
<ul>
<li><span class="text-success">Male ≥50 yrs, one or more negative PBs, again highly suspicious for prostatic CA.</span></li>
</ul>
</li>
<li><em>why?</em>
<ol>
<li>CA detection rate 6% at PCA3 &#x3C;5 to 57% at PCA3 >100.</li>
<li>Sensitivity &#x26; specificity of PCA3 score of 35 are- 48% &#x26; 78% who underwent 10 core 2 sets repeat PB at 2 &#x26; 4 yr follow up.</li>
<li>Superior than %fPSA.</li>
</ol>
</li>
</ul>
</li>
</ul>
<h4 id="d-3-dilemma-if-initial-bx-showed-hgpin-15-20"><code>D-3) Dilemma if initial bx showed HGPIN (15-20%):</code></h4>
<p><strong>What next ?</strong></p>
<ul>
<li>Single core
<ul>
<li>No RPB</li>
<li>Why?
<ul>
<li>Because unrelated to Pca risk</li>
</ul>
</li>
</ul>
</li>
<li>Multifocal
<ul>
<li>RPB within 1 yr after initial bx</li>
<li>“Delayed interval” PB every 3 yrs-( GODOY et al).</li>
<li>Why?
<ul>
<li>Because risk of CA on RPB - 40%</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="d-4-dilemma-if-initial-bx-showed---asap-5"><code>D-4) Dilemma if initial bx showed - ASAP (5%):</code></h4>
<p><strong>What next?</strong></p>
<ul>
<li>RPB within 3-6 months</li>
</ul>
<p><strong>Why?</strong></p>
<ul>
<li>Because 40% chance of cancer detection on RPB.</li>
</ul>
<h4 id="d-5-dilemma-in-techniques--no-of-cores--sampling-location-during-initial-bx"><code>D-5) Dilemma in techniques / no of cores / sampling location during initial bx:</code></h4>
<p><span class="text-primary"><strong>Sextant? / 10 cores? / 12 cores? / more?</strong></span></p>
<p><em>Current recommendation:</em></p>
<ul>
<li>
<p><span class="text-success">10-12 core extended PB scheme, with additional cores from suspected area on DRE/TRUS is the most accepted method.</span></p>
<p>(some authors recommend adding a core from <span class="text-primary">extreme apex</span> on each side, because this is the <em>m/c</em> site where CA is missed during initial bx)</p>
</li>
</ul>
<p><strong>What is extended PB scheme?</strong></p>
<p>sextant template + at least 4 &#x26; up to 8 laterally directed sampling from PZ.</p>
<p>Usually <span class="text-success">12 cores</span>.</p>
<p><strong>Advantage?</strong></p>
<p>Superior detection rate.</p>
<p><strong>Vienna nomogram</strong> suggested (8-18) cores, based on pt age &#x26; gland volume, in PSA 2-10 ng/ml to ensure 90% certainty.</p>
<p>(for example= prostate size of 50-60 ml in pt &#x3C;50yrs, 50s, 60s, 70s- 16, 14, 12 or 10 cores were prescribed respectively)</p>
<p><em>Most initial bx shown = further increase in no of bx core >12 has no significant benefit.</em></p>
<h4 id="d-6-repeat-pb--whats-the-optimal-technique"><code>D-6) Repeat PB – what’s the optimal technique?</code></h4>
<ul>
<li><span class="text-danger"><strong>Controversial.</strong></span></li>
<li><span class="text-primary"><em>Recommendation</em></span> is 10-12 cores extended bx, with additional core from suspected area by modern imaging.</li>
</ul>
<p>Recently Scattoni et al developed some model,</p>















<table><thead><tr><th>Pt with previous ASAP</th><th>Pt with %fPSA &#x3C;10%</th><th>Pt with %fPSA>10% but no ASAP</th></tr></thead><tbody><tr><td>14 core without TZ sampling</td><td>14 core bx with 4 TZ core</td><td>20 core bx with 4 TZ core</td></tr></tbody></table>
<p><code>Algorithm for pt with prior negative biopsy (AUA updates 2012-1)</code></p>
<ul>
<li>
<p>Assessing the <strong>adequacy of initial biopsy</strong>.</p>
<p>↓</p>
</li>
<li>
<p><strong>F/T PSA</strong> is currently the <strong>most useful</strong> for predicting cancer on repeat biopsy.</p>
<p>(Newer marker such as PCA-3 and %(-2) proPSA are promising)</p>
<p>↓</p>
</li>
<li>
<p><strong>Repeat bx include a minimum of 14 cores</strong></p>
<p>(12 cores recommended for initial biopsy plus 2 additional core from right and left anterior apex)</p>
<p>(The yeild from transition zone is low)</p>
<p>↓</p>
</li>
<li>
<p><strong>Fail to identify CA</strong></p>
<p>↓</p>
</li>
<li>
<p><strong>Saturation biopsy (>20 cores) is warranted</strong></p>
<ul>
<li><span class="text-primary">After 2 negative saturation biopsy , finding of cancer is extremely low and if found, the significance of the cancer is questionable.</span></li>
</ul>
</li>
</ul>
<p><code>mp-MRI – (Multiparametric-MRI) for Prostate-malignancy</code></p>
<ul>
<li>
<p>Includes T1 and T2 weighted sequences with at least 2 functional parameters–</p>
<ul>
<li>
<p>dynamic contrast enhancement (DCE),</p>
</li>
<li>
<p>diffusion-weighted imaging (DWI),</p>
</li>
<li>
<p>apparent diffusion coefficient (ADC) mapping</p>
</li>
<li>
<p>and magnetic resonance spectroscopy (MRS).</p>
</li>
</ul>
</li>
</ul>
<p><code>Q) Does mpMRI have a role in ruling-in and ruling-out clinically significant prostate cancer in men at risk prior to biopsy ?</code></p>
<ul>
<li>
<p>MRI may rule out significant cancer and avoid a second biopsy series in case of persistent elevated PSA.</p>
</li>
<li>
<p>There is clear evidence that targeting biopsies to areas suspicious for malignancy at mpMRI can <em>reveal a greater volume of cancers and a higher grade</em> than systematic 12-core biopsies.</p>
</li>
</ul>
<p>Pt had high PSA &#x26; negative TRUS–bx. Later Cancer confirmed on MR-bx</p>
<p><img src="https://drdebasismaity.github.io/discussions/CA_Prostate_mri.jpg" alt="CA Prostate MRI"></p>
<hr>
<p><code>MRI for the Detection, Localisation, and Characterisation of Prostate Cancer:</code></p>
<p><em>Recommendations from a European Consensus Meeting–</em></p>
<ul>
<li>Diffusion weighted MR (DW-MR) sequence is <strong>appropriate</strong> in detection of any cancer in PZ</li>
<li>The Gleason grade of lesions in the PZ</li>
</ul>
<ol>
<li><em>exclusion of clinically significant disease as defined by a lesion size ≥0.2 cm3 (approximately 7 mm) in PZ,</em></li>
<li><em>exclusion of clinically significant disease as defined by a lesion size ≥0.5ml, in the PZ &#x26;</em></li>
<li><em>exclusion of clinically significant cancer according to the definition of a lesion ≥0.5 cm3 and/or Gleason ≥4 + 3 in the PZ.</em></li>
</ol>
<p><code>TRUS (Trans Rectal Ultrasonography):</code></p>
<ul>
<li>Uses:</li>
</ul>
<ol>
<li>Biopsy</li>
<li>Cancer Screening</li>
<li>Prostate Gland Measurement and Calculation PSA Gland Density</li>
</ol>
<ul>
<li>Advantages:</li>
</ul>
<ol>
<li>Simple out-patient procedure</li>
<li>Reasonably well tolerated</li>
<li>Inexpensive</li>
</ol>
<ul>
<li>Disadvantages:</li>
</ul>
<ol>
<li>Low sensitivity, low PPV</li>
<li>Large inter-observer variability</li>
<li>Trans-rectal approach is irritable for some</li>
</ol>
<h4 id="d-7-diagnostic-dilemma-in-histopathology-report-following-robot-assisted-laparoscopic-prostatectomy"><code>D-7) Diagnostic dilemma in histopathology report following robot assisted laparoscopic prostatectomy:</code></h4>
<ul>
<li>There are reports in literature about the <span class="text-primary"><em>‘vanishing cancer syndrome’</em></span> - the phenomenon of not finding any cancer in the radical prostatectomy specimen, despite a positive needle biopsy.</li>
<li>This has important medico legal implications-</li>
<li>Pt may feel that surgery has been performed unnecessarily or worse, still that cancer has been left behind in their body.</li>
<li>Many benign conditions like Benign atrophy, post-atrophic hyperplasia, atypical adenomatous hyperplasia, seminal vesicle-type tissue, Cowper’s gland, and inflammatory processes like granulomatous prostatitis, xanthogranulomatous prostatitis and malakoplakia may be misinterpreted as adenocarcinoma in initial bx.</li>
<li>In such cases use of <em>immunohistochemical stains like p63, CAM 5.2, 34βE12 and AMACR</em> may help in diagnosis.</li>
</ul>
<h4 id="d-8diagnostic-dilemma-in-histopathology-report-following-radical-prostatectomy"><code>D-8)Diagnostic dilemma in histopathology report following radical prostatectomy:</code></h4>
<p><img src="https://drdebasismaity.github.io/discussions/CA_Prostate_bx-1.png" alt="CA Prostate BX"></p>
<p><em>TRUS biopsy showing adenocarcinoma prostate Gleason Score 3 + 3 = 6</em></p>
<hr>
<p><strong>BUT</strong></p>
<hr>
<p><img src="https://drdebasismaity.github.io/discussions/CA_Prostate_bx-2.png" alt="CA Prostate BX"></p>
<p><em>Final histopathology slides of radical prostatectomy</em></p>
<hr>
<p>specimen of same patient showing no tumor.</p>
<hr>
<p><img src="https://drdebasismaity.github.io/discussions/CA_Prostate_bx-3.png" alt="CA Prostate BX"></p>
<p><em>Negative AMACR staining</em></p> </div> </div> </div> </body></html> 